Valuation: MultiCell Technologies, Inc.

Market Cap 1.5M 1.33M 1.25M 1.14M 2.14M 144M 2.17M 15.08M 5.84M 73.57M 5.63M 5.51M 236M P/E 2013
-1.09x
P/E 2014 -4.9x
Enterprise Value 1.59M 1.41M 1.32M 1.2M 2.27M 153M 2.3M 15.98M 6.19M 77.98M 5.97M 5.84M 250M EV / Sales 2013
34.9x
EV / Sales 2014 45.7x
Free-Float
90.01%
Yield 2013 *
-
Yield 2014 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-15.38% - - 5K
+4.16%+3.04%+49.37%+94.17% 74.41B
-3.11%-3.53%+21.92%+74.60% 59.26B
+0.89%-0.63%+4.28%+34.51% 47.14B
-0.45%-4.14%+26.83%+33.68% 42.91B
+1.05%+1.59%+355.63%+695.66% 44.13B
-1.97%-2.85%+1.57%+96.40% 40.79B
-0.54%+2.93%+9.50%+50.41% 30.77B
-2.68%+5.11%+33.11%+19.50% 29.31B
+0.36%-7.28%-28.50%+330.63% 23.71B
Average -0.22%-0.64%+52.63%+158.84% 43.6B
Weighted average by Cap. +0.08%-0.40%+57.77%+150.58%

Financials

2013 2014
Net sales 49.32K 43.8K 40.96K 37.33K 70.28K 4.75M 71.24K 496K 192K 2.42M 185K 181K 7.77M 49.32K 43.8K 40.96K 37.33K 70.28K 4.75M 71.24K 496K 192K 2.42M 185K 181K 7.77M
Net income -1.23M -1.1M -1.03M -935K -1.76M -119M -1.78M -12.41M -4.8M -60.54M -4.64M -4.53M -194M -380K -338K -316K -288K -542K -36.59M -549K -3.82M -1.48M -18.64M -1.43M -1.4M -59.86M
Net Debt -39.11K -34.74K -32.48K -29.6K -55.73K -3.77M -56.5K -393K -152K -1.92M -147K -144K -6.16M 90.04K 79.98K 74.79K 68.16K 128K 8.67M 130K 905K 350K 4.42M 338K 331K 14.18M
Logo MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company. The Company and its subsidiaries are developing therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology, and peripheral vessel applications. The Company's portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development, and includes MCT-125, MCT-465, MCT-475 and MCT-485. MCT-125 is a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue. MCT-465 is a preclinical synthetic double-stranded ribonucleic acid (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers. MCT-475 is a discovery-stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers. MCT-485 is a discovery-stage dsRNA therapeutic candidate for the treatment of certain cancers.
Employees
-